Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000628914 | SCV000749822 | likely pathogenic | Hypertrophic cardiomyopathy | 2017-11-16 | criteria provided, single submitter | clinical testing | This sequence change replaces serine with proline at codon 1550 of the MYH7 protein (p.Ser1550Pro). The serine residue is highly conserved and there is a moderate physicochemical difference between serine and proline. This variant is not present in population databases (ExAC no frequency). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has been reported to be de novo in individuals affected with myopathy (Invitae). |
Revvity Omics, |
RCV003129948 | SCV003815405 | uncertain significance | not provided | 2021-04-29 | criteria provided, single submitter | clinical testing |